ARS Pharmaceuticals, Inc. Proceeds from Sale of Productive Assets
ARS Pharmaceuticals, Inc. (SPRY) reported Proceeds from Sale of Productive Assets of $1.30 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2022-11-02
- 2022-09-30: Proceeds from Sale of Productive Assets 9 month $1.30M.
| Period end | Proceeds from Sale of Productive Assets 9 month |
|---|---|
| 2022-09-30 | $1.30M 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |